Revolution Medicines starts Phase 3 trial of zoldonrasib combo for metastatic RAS G12D NSCLC patients

Revolution Medicines has initiated treatment in its global Phase 3 RASolve 308 trial, testing zoldonrasib combined with pembrolizumab and chemotherapy as a first-line therapy for metastatic RAS G12D non-squamous non-small cell lung cancer (NSCLC). This patient group, representing about 4% of NSCLC cases, currently lacks approved targeted treatments. Early data showed promising anti-tumor activity and safety, supporting further study. The trial aims to improve progression-free survival and other outcomes, potentially establishing a new standard for treating RAS-driven cancers.

As of Oct 20, 2026 19:11 WIB, Revolution Medicines Inc. (RVMD) trades at USD 183.00 on Pluang, showing a modest 0.47% gain for the day. The company holds a market capitalization of $39.03 billion and an enterprise value of $35.73 billion, reflecting its significant presence in the health sector. This trading data provides context to the ongoing Phase 3 RASolve 308 trial developments.